Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.65 |
| ▸ | PGR | P06401 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.65 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.65 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8846925 | 1.00 | AR (0.65) | ARLMNANR3C1PGRCYP3A4 | |
| SCHEMBL5296168 | 1.00 | AR (0.65) | ARLMNANR3C1PGRCYP3A4 | |
| SCHEMBL8846916 | 1.00 | AR (0.65) | ARLMNANR3C1PGRCYP3A4 | |
| SCHEMBL259433 | 1.00 | AR (0.65) | ARLMNANR3C1PGRCYP3A4 | |
| SCHEMBL18812341 | 0.94 | LMNA (0.66) | ARLMNANR3C1PGRCYP3A4 | |
| SCHEMBL11644576 | 0.89 | LMNA (0.65) | ARLMNANR3C1PGRCYP3A4 | |
| SCHEMBL11644583 | 0.89 | LMNA (0.65) | ARLMNANR3C1PGRCYP3A4 | |
| SCHEMBL7787111 | 0.89 | AR (0.62) | ARLMNANR3C1PGRCYP3A4 | |
| SCHEMBL9404138 | 0.89 | AR (0.62) | ARLMNANR3C1PGRCYP3A4 | |
| SCHEMBL11646428 | 0.86 | AR (0.61) | ARLMNANR3C1PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242552-A1 | New use of antimineralocorticoid compounds against narcotic withdrawal syndrome | AVENTIS PHARMA S.A. | 2004-12-02 | — | — | US | claimed |
| EP-0863760-B1 | USE OF ANTIMINERALOCORTICOID COMPOUNDS AGAINST DRUG WITHDRAWAL SYNDROME | AVENTIS PHARMA SA (FR) | 2001-12-05 | — | — | EP | claimed |
| JP-56118100-A | — | — | None | — | — | JP | disclosed |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200361866-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-11-19 | — | — | US | disclosed |
| US-10730831-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190040006-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-02-07 | — | — | US | disclosed |
| US-10106500-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170247325-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-08-31 | — | — | US | disclosed |
| US-9675583-B2 | Selective androgen receptor modulators (SARMS) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160038461-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-02-11 | — | — | US | disclosed |
| EP-0479777-A1 | SPIRONOLACTONE COMPOSITION. | CAROLINA MEDICAL PRODUCTS INC (US) | 1992-04-15 | — | — | EP | disclosed |
| EP-0479777-A4 | SPIRONOLACTONE COMPOSITION. | CAROLINA MEDICAL PRODUCTS INC (US) | 1991-12-16 | — | — | EP | disclosed |
| WO-1990011077-A1 | SPIRONOLACTONE COMPOSITION | CAROLINA MEDICAL PRODUCTS, INC. (US) | 1990-10-04 | — | — | WO | disclosed |
| US-4837211-A | DIURETIC, ALDOSTERONE ANTAGONIST | CAROLINA MEDICAL PRODUCTS, INC. (US) | 1989-06-06 | — | — | US | disclosed |
| US-4323500-A | REACTING WITH A THIOCARBOXYLIC ACID | MITSUBISHI CHEMICAL INDUSTRIES, LIMITED (JP) | 1982-04-06 | — | — | US | disclosed |
| US-4323500-A | REACTING WITH A THIOCARBOXYLIC ACID | MITSUBISHI CHEMICAL INDUSTRIES, LIMITED (JP) | 1982-04-06 | — | — | US | disclosed |
| JP-S56118100-A | PREPARATION OF 7ALPHA-ACETYLTHIO-17-HYDROXY-3-OXO-17ALPHA-PREGN- 4-ENE-21-CARBOXYLIC ACID GAMMA-LACTONE | MITSUBISHI CHEM IND LTD | 1981-09-16 | — | — | JP | disclosed |
| US-4213902-A | Process for producing steroidal 7α-acylthio-4-en-3-ones | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1980-07-22 | — | — | US | disclosed |
| US-4057543-A | Process for the preparation of 17β-hydroxy-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone | G. D. SEARLE & CO. (US) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361866-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | AR 1/4885LMNA 3992/4885NR3C1 26/4885 |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | AR 1/4885LMNA 4044/4885NR3C1 31/4885 |
| US-20040242552-A1 | New use of antimineralocorticoid compounds against narcotic withdrawal syndrome | OPRM1, PNMT, SLC6A11 | AR 2209/4885LMNA 3096/4885NR3C1 40/4885 |
| US-20170247325-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | AR 1/4885LMNA 3992/4885NR3C1 26/4885 |
| US-10106500-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | AR 1/4885LMNA 4044/4885NR3C1 31/4885 |
| US-20160038461-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | AR 1/4885LMNA 3992/4885NR3C1 26/4885 |
| US-20190040006-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | AR 1/4885LMNA 3992/4885NR3C1 26/4885 |
| US-10730831-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | AR 1/4885LMNA 4044/4885NR3C1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.